AGEs, RAGE, and Diabetic Retinopathy

被引:190
作者
Zong, Hongliang [1 ]
Ward, Micheal [1 ]
Stitt, Alan W. [1 ]
机构
[1] Queens Univ Belfast, Ctr Vis & Vasc Sci, Royal Victoria Hosp, Belfast BT12 6BA, Antrim, North Ireland
关键词
Diabetic retinopathy; Advanced glycation end products (AGEs); Receptor for AGEs (RAGE); Inflammation; RAGE blockade; GLYCATION END-PRODUCTS; ENDOTHELIAL GROWTH-FACTOR; CYTOPLASMIC DOMAIN; SIGNALING PATHWAYS; FACTOR EXPRESSION; OXIDATIVE STRESS; CELL-SURFACE; RECEPTOR; DYSFUNCTION; ACTIVATION;
D O I
10.1007/s11892-011-0198-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetic retinopathy is a major diabetic complication with a highly complex etiology. Although there are many pathways involved, it has become established that chronic exposure of the retina to hyperglycemia gives rise to accumulation of advanced glycation end products (AGEs) that play an important role in retinopathy. In addition, the receptor for AGEs (RAGE) is ubiquitously expressed in various retinal cells and is upregulated in the retinas of diabetic patients, resulting in activation of pro-oxidant and proinflammatory signaling pathways. This AGE-RAGE axis appears to play a central role in the sustained inflammation, neurodegeneration, and retinal microvascular dysfunction occurring during diabetic retinopathy. The nature of AGE formation and RAGE signaling bring forward possibilities for therapeutic intervention. The multiple components of the AGE-RAGE axis, including signal transduction, formation of ligands, and the end-point effectors, may be promising targets for strategies to treat diabetic retinopathy.
引用
收藏
页码:244 / 252
页数:9
相关论文
共 67 条
[1]  
Abdallah Walid, 2009, Int Ophthalmol Clin, V49, P95, DOI 10.1097/IIO.0b013e31819fd84a
[2]   Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy [J].
Arevalo, J. F. ;
Maia, M. ;
Flynn, H. W., Jr. ;
Saravia, M. ;
Avery, R. L. ;
Wu, L. ;
Farah, M. Eid ;
Pieramici, D. J. ;
Berrocal, M. H. ;
Sanchez, J. G. .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2008, 92 (02) :213-216
[3]   The RAGE axis in early diabetic retinopathy [J].
Barile, GR ;
Pachydaki, SI ;
Tari, SR ;
Lee, SE ;
Donmoyer, CM ;
Ma, WC ;
Rong, LL ;
Buciarelli, LG ;
Wendt, T ;
Hörig, H ;
Hudson, BI ;
Qu, W ;
Weinberg, AD ;
Yan, SF ;
Schmidt, AM .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46 (08) :2916-2924
[4]   A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats [J].
Bhatwadekar, A. ;
Glenn, J. V. ;
Figarola, J. L. ;
Scott, S. ;
Gardiner, T. A. ;
Rahbar, S. ;
Stitt, A. W. .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2008, 92 (04) :545-547
[5]  
BIANCHI R, 2011, J BIOL CHEM
[6]   Oxidative stress-inducing carbonyl compounds from common foods: Novel mediators of cellular dysfunction [J].
Cai, WJ ;
Gao, QD ;
Zhu, L ;
Peppa, M ;
He, CJ ;
Vlassara, H .
MOLECULAR MEDICINE, 2002, 8 (07) :337-346
[7]   Inhibition of Advanced Glycation and Absence of Galectin-3 Prevent Blood-Retinal Barrier Dysfunction during Short-Term Diabetes [J].
Canning, Paul ;
Glenn, Josephine V. ;
Hsu, Daniel K. ;
Liu, Fu-Tong ;
Gardiner, Tom A. ;
Stitt, Alan W. .
EXPERIMENTAL DIABETES RESEARCH, 2007,
[8]   Association of dietary AGEs with circulating AGEs, glycated LDL, IL-1α and MCP-1 levels in type 2 diabetic patients [J].
Chao, Pei-chun ;
Huang, Chien-ning ;
Hsu, Cheng-chin ;
Yin, Mei-chin ;
Guo, Yu-ru .
EUROPEAN JOURNAL OF NUTRITION, 2010, 49 (07) :429-434
[9]   Advanced glycation end-products induce apoptosis involving the signaling pathways of oxidative stress in bovine retinal pericytes [J].
Chen, Bai-Hua ;
Jiang, De-Yong ;
Tang, Luo-Sheng .
LIFE SCIENCES, 2006, 79 (11) :1040-1048
[10]   RAGE ligation affects T cell activation and controls T cell differentiation [J].
Chen, Yali ;
Akirav, Eitan M. ;
Chen, Wei ;
Henegariu, Octavian ;
Moser, Bernhard ;
Desai, Dharmesh ;
Shen, Jane M. ;
Webster, Jeffery C. ;
Andrews, Robert C. ;
Mjalli, Adnan M. ;
Rothlein, Robert ;
Schmidt, Ann Marie ;
Clynes, Raphael ;
Herold, Kevan C. .
JOURNAL OF IMMUNOLOGY, 2008, 181 (06) :4272-4278